Selio Medical obtained FDA clearance for a hydrogel device designed to seal CT-guided lung biopsy punctures before pneumothorax can occur. The product targets the most common and costly complication of lung biopsies, which affects up to a third of the more than 800,000 such biopsies performed annually in the U.S. The development centers on a procedural safety improvement rather than a therapeutic mechanism, aiming to reduce post-procedure complications by physically sealing the puncture site. For interventional oncology and pulmonary diagnostics, pneumothorax risk affects throughput, patient management, and downstream imaging and observation requirements. The clearance also broadens the opportunity for imaging-guided procedural devices that can standardize complication prevention across centers.